Opna Bio

Executive Summary

Opna Bio is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, dedicated to developing novel oncology therapeutics. Founded in 2021, the company focuses on rationally designed epigenetic modulators and protein degraders targeting key regulators of cancer. Its lead programs address hematologic malignancies, including myelofibrosis and multiple myeloma, and are currently in Phase 1 clinical development. Opna Bio's approach leverages deep expertise in epigenetics and targeted protein degradation to create differentiated therapies with potential for improved efficacy and safety. Despite being private with limited public data, the company's focus on high-unmet-need indications and its innovative platform position it as an emerging player in the oncology landscape. Near-term milestones, including initial clinical data readouts, will be critical for validating its technology and advancing its pipeline.

Upcoming Catalysts (preview)

• Q1 2027Phase 1 data readout for lead candidate in myelofibrosis40% success
• Q2 2027IND filing for second program in multiple myeloma60% success
• TBDPotential partnership or licensing deal for epigenetic platform30% success